Clinical Trial

A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 27, 2024 (before its estimated November 2024 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the efficacy and safety of JPI-547, a PARP/TNKS dual inhibitor in Platinum-resistant, advanced/relapsed ovarian cancer subjects previously treated with a PARP inhibitor
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-07-24.
Status change: Not Yet Recruiting → Active, Not Recruiting 2024-08-22
Trial Details
NCT Number NCT05475184
Lead Sponsor Onconic Therapeutics Inc.
Conditions Ovarian Cancer
Enrollment 58 participants
Start Date 2022-08-31
Primary Completion 2024-11 (estimated)
Study Completion 2025-06 (estimated)
Updated on ClinicalTrials.gov 2024-08-27